Prostate Cancer in Elderly Men. Screening, Active Surveillance, and Definitive Therapy

Clinics in Geriatric Medicine

Volumn 31, Issue 4, 2015, Pages 615-629

  Roussel, Breton ^a   Ouellet, Gregory M ^b   Mohile, Supriya G ^c   Dale, William ^d  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

Aging; CGA; Geriatric oncology; Geriatrics; Prostate cancer; Shared decision making

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; DOCETAXEL; MITOXANTRONE; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

AGE DISTRIBUTION; ANDROGEN DEPRIVATION THERAPY; BONE METASTASIS; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COMORBIDITY; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; FUNCTIONAL ASSESSMENT; GERIATRIC ASSESSMENT; GERIATRICS; HUMAN; HYPOCALCEMIA; INTENSITY MODULATED RADIATION THERAPY; JAW OSTEONECROSIS; KIDNEY DISEASE; LIFE EXPECTANCY; MEDICAL DECISION MAKING; METASTASIS POTENTIAL; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PATIENT COUNSELING; PATIENT MONITORING; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; PROTON THERAPY; QUALITY OF LIFE; REVIEW; ROBOT ASSISTED SURGERY; SEXUAL DYSFUNCTION; TREATMENT INDICATION; TREATMENT PLANNING; TUMOR INVASION; URINE INCONTINENCE; AGED; BLOOD; DECISION MAKING; MALE; MASS SCREENING; PATIENT CARE PLANNING; PROCEDURES; PROSTATIC NEOPLASMS; WATCHFUL WAITING;

AGED; DECISION MAKING; HUMANS; MALE; MASS SCREENING; PATIENT CARE PLANNING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; WATCHFUL WAITING;

EID: 84973408666     PISSN: 07490690     EISSN: 18798853     Source Type: Journal    
DOI: 10.1016/j.cger.2015.07.004     Document Type: Review

References (82)

1. Estimated number of new cancer cases and deaths by sex, US. Atlanta, GA: American Cancer Society; 2015. Available at: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/index.
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008. Report based on November 2010 SEER data submission, posted to the SEER web site. Bethesda, MD: National Cancer Institute; 2011. Available at. http://seer.cancer.gov/csr/1975_2008/.
3. Hampson LA, Cowan JE, Zhao S, et al. Impact of age on quality-of-life outcomes after treatment for localized prostate cancer. Eur Urol 2015;68(3):480-6.
4. Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157(2):120-34.
5. Herrera AP, Snipes SA, King DW, et al. Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. Am J Public Health 2010;100(Suppl 1):S105-12.
6. Rider JR, Sandin F, Andrén O, et al. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol 2013;63(1):88-96.
7. Droz JP, Aapro M, Balducci L, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 2014;15(9):e404-14.
8. Qaseem A, Barry MJ, Denberg TD, et al. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2013;158(10):761-9.
9. Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CACancer JClin 2010;60(2):70-98.
10. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA Guideline. J Urol 2013;190(2):419-26.
11. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384(9959):2027-35.
12. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11(8):725-32.
13. Ilic D, Neuberger MM, Djulbegovic M, et al. Screening for prostate cancer. Cochrane Database Syst Rev 2013;(1):CD004720.
14. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104(2):125-32.
15. Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010;341. c4543.
16. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370(10):932-42.
17. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367(3):203-13.
18. Lee SJ, Lindquist K, Segal MR, et al. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2006;295(7):801-8.
19. Schonberg MA, Davis RB, McCarthy EP, et al. Index to predict 5-year mortality of community-dwelling adults aged 65 and older using data from the National Health Interview Survey. J Gen Intern Med 2009;24(10):1115-22.
20. Schonberg MA, Davis RB, McCarthy EP, et al. External validation of an index to predict up to 9-year mortality of community-dwelling adults aged 65 and older. J Am Geriatr Soc 2011;59(8):1444-51.
21. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA 2011;305(1):50-8.
22. Leong DP, Teo KK, Rangarajan S, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet 2015;386: 266-73.
23. Kotwal AA, Mohile SG, Dale W. Remaining life expectancy measurement and PSA screening of older men. J Geriatr Oncol 2012;3(3):196-204.
24. Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155(11):762-71.
25. Walter LC, Bertenthal D, Lindquist K, et al. PSA screening among elderly men with limited life expectancies. JAMA 2006;296(19):2336-42.
26. Hoffman RM, Couper MP, Zikmund-Fisher BJ, et al. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study). Arch Intern Med 2009;169(17):1611-8.
27. Drazer MW, Prasad SM, Huo D, et al. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer 2014;120(10):1491-8.
28. Dale W. Prostate cancer: PSA testing in older men-are we following the guidelines? Nat Rev Urol 2012;9(7):357-8.
29. Fung C, Dale W, Mohile SG. Prostate cancer in the elderly patient. J Clin Oncol 2014;32(24):2523-30.
30. Margel D, Nandy I, Wilson TH, et al. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study. J Urol 2013;190(6):2039-45.
31. Christie DR, Sharpley CF, Bitsika V. Why do patients regret their prostate cancer treatment? A systematic review of regret after treatment for localized prostate cancer. Psychooncology 2015. [Epub ahead of print].
32. Novara G, Ficarra V, D'Elia C, et al. Prospective evaluation with standardised criteria for postoperative complications after robotic-assisted laparoscopic radical prostatectomy. Eur Urol 2010;57(3):363-70.
33. Walter LC, Covinsky KE. Cancer screening in elderly patients. JAMA 2001; 285(21):2750.
34. Alibhai SM, Leach M, Tomlinson G, et al. 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst 2005;97(20):1525-32.
35. PACE Participants, Audisio RA, Pope D, et al. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol 2008;65(2):156-63.
36. Schwartz KL, Alibhai SM, Tomlinson G, et al. Continued undertreatment of older men with localized prostate cancer. Urology 2003;62(5):860-5.
37. Alibhai SM, Krahn MD, Cohen MM, et al. Is there age bias in the treatment of localized prostate carcinoma? Cancer 2004;100(1):72-81.
38. Schymura MJ, Kahn AR, German RR, et al. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer 2010;10:152.
39. Abdollah F, Sun M, Schmitges J, et al. Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort. Eur Urol 2011;60(5):920-30.
40. Kane CJ, Im R, Amling CL, et al. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology 2010;76(3):695-700.
41. De Carlo F, Celestino F, Verri C, et al. Retropubic, laparoscopic, and robotassisted radical prostatectomy: surgical, oncological, and functional outcomes: a systematic review. Urol Int 2014;93(4):373-83.
42. Pilecki MA, McGuire BB, Jain U, et al. National multi-institutional comparison of 30-day postoperative complication and readmission rates between open retropubic radical prostatectomy and robot-assisted laparoscopic prostatectomy using NSQIP. J Endourol 2014;28(4):430-6.
43. Porpiglia F, Morra I, Lucci Chiarissi M, et al. Randomised controlled trial comparing laparoscopic and robot-assisted radical prostatectomy. Eur Urol 2013;63(4):606-14.
44. Basto MY, Vidyasagar C, te Marvelde L, et al. Early urinary continence recovery after robot-assisted radical prostatectomy in older Australian men. BJU Int 2014; 114(Suppl 1):29-33.
45. Kumar A, Samavedi S, Bates AS, et al. Age stratified comparative analysis of perioperative, functional and oncologic outcomes in patients after robot assisted radical prostatectomy-a propensity score matched study. Eur J Surg Oncol 2015;41(7):837-43.
46. Frank SJ, Pisters LL, Davis J, et al. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol 2007;177(6):2151-6 [discussion: 2156].
47. Grant JD, Litwin MS, Kwan L, et al. Does hormone therapy exacerbate the adverse effects of radiotherapy in men with prostate cancer? A quality of life study. J Urol 2011;185(5):1674-80.
48. Zapatero A, Guerrero A, Maldonado X, et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol 2015;16(3):320-7.
49. Mohler JL. Concept and viability of androgen annihilation for advanced prostate cancer. Cancer 2014;120(17):2628-37.
50. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010;8(2):162-200.
51. Cancado BL, Miranda LC, Madeira M, et al. Importance of bone assessment and prevention of osteoporotic fracture in patients with prostate cancer in the gonadotropic hormone analogues use. Rev Col Bras Cir 2015;42(1):62-6.
52. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352(2):154-64.
53. Smith MR, Saad F, Egerdie B, et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol 2009;182(6):2670-5.
54. Klotz LH, McNeill IY, Kebabdjian M, et al. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study. Eur Urol 2013;63(5):927-35.
55. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94(19):1458-68.
56. Henry D, Vadhan-Raj S, Hirsh V, et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer 2014;22(3):679-87.
57. Wirth M, Tammela T, Cicalese V, et al. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). Eur Urol 2015; 67(3):482-91.
58. Bosco C, Bosnyak Z, Malmberg A, et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol 2014;14:1222-6.
59. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24(27):4448-56.
60. Nguyen PL, Chen MH, Beckman JA, et al. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys 2012;82(4):1411-6.
61. Morgans AK, Fan KH, Koyama T, et al. Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy. J Urol 2015;193(4):1226-31.
62. Chang D, Joseph DJ, Ebert MA, et al. Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer. J Med Imaging Radiat Oncol 2014;58(2):223-8.
63. Bylow K, Dale W, Mustian K, et al. Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy. Urology 2008;72(2):422-7.
64. Bylow K, Mohile SG, Stadler WM, et al. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review. Cancer 2007;110(12):2604-13.
65. Bylow K, Hemmerich J, Mohile SG, et al. Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case-control study. Urology 2011;77(4):934-40.
66. Galvao DA, Taaffe DR, Spry N, et al. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 2010;28(2):340-7.
67. Gardner JR, Livingston PM, Fraser SF. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgendeprivation therapy: a systematic review. J Clin Oncol 2014;32(4):335-46.
68. Winters-Stone KM, Dobek JC, Bennett JA, et al. Resistance training reduces disability in prostate cancer survivors on androgen deprivation therapy: evidence from a randomized controlled trial. Arch Phys Med Rehabil 2015;96(1):7-14.
69. Jamadar RJ, Winters MJ, Maki PM. Cognitive changes associated with ADT: a review of the literature. Asian J Androl 2012;14(2):232-8.
70. Yang J, Zhong F, Qiu J, et al. Cognitive function in Chinese prostate cancer patients on androgen-deprivation therapy: a cross-sectional study. Asia Pac J Clin Oncol 2015. [Epub ahead of print].
71. Mohile SG, Lacy M, Rodin M, et al. Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer. Crit Rev Oncol Hematol 2010; 75(2):152-9.
72. Bourke L, Boorjian SA, Briganti A, et al. Survivorship and improving quality of life in men with prostate cancer. Eur Urol 2015. [Epub ahead of print].
73. Alva A, Hussain M. Intermittent androgen deprivation therapy in advanced prostate cancer. Curr Treat Options Oncol 2014;15(1):127-36.
74. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26(2):242-5.
75. Wong H-L, Lok SW, Wong S, et al. Docetaxel in very elderly men with metastatic castration-resistant prostate cancer. Prostate Int 2015;3(2):42-6.
76. Shigeta K, Kosaka T, Yazawa S, et al. Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer. Int J Clin Oncol 2015;20(3):605-12.
77. Leibowitz-Amit R, Templeton AJ, Alibhai SM, et al. Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer. J Geriatr Oncol 2015;6(1):23-8.
78. Italiano A, Ortholan C, Oudard S, et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 2009;55(6):1368-75.
79. Fizazi K, Faivre L, Lesaunier F, et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol 2015;16(7):787-94.
80. James ND, Mason SM, Clarke NW, et al. Docetaxel and/or zoledronic acid for hormone- naïve prostate cancer: first overall survival results from STAMPEDE (NCT00268476). J Clin Oncol 2015;33(15 Suppl):2001, 2015 ASCO Annual Meeting. [abstract: 5001].
81. Hoppe S, Rainfray M, Fonck M, et al. Functional decline in older patients with cancer receiving first-line chemotherapy. J Clin Oncol 2013;31(31):3877-82.
82. Ward PR, Wong MD, Moore R, et al. Fall-related injuries in elderly cancer patients treated with neurotoxic chemotherapy: a retrospective cohort study. J Geriatr Oncol 2014;5(1):57-64.